BLUEHOLE-NEW-CONSUMPTION
14.3.2022 07:50:03 CET | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on China's First Corporate Risk Assessment Laboratory for the European Union Tobacco Products Directive Compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220313005043/en/
Here below is the full article:
SMOORE, a global leader in offering vaping technology solutions, today announced an industry-leading risk assessment laboratory for the European Union Tobacco Product Directive (EUTPD) compliance. Thus, SMOORE has become China's first company capable of providing vaping products with one-stop TPD risk assessment service. Belonging to SMOORE fundamental research center, the laboratory will be a hub to empower more vaping brands to comply with the safety standards of EUTPD, thereby meeting the EU vaping market entry requirements.
This laboratory has begun operation in the first half of 2021, and already completed 52 product tests for several world-leading vape brands. As China’s first corporate TPD-compliant risk assessment laboratory, it can generate test reports within 5 working days. Its laboratory equipment is benchmarked against those in world-class analytical testing laboratories, such as Labstat and Enthalpy.
Entering into force in 2014, the TPD is a unified directive for tobacco regulations in the 27 EU Member States. It regulates the sale, presentation and manufacture of all tobacco products, including e-cigarettes, in the EU. For the sake of quality control and public health protection, the TPD sets specific safety requirements for the content of e-cigarettes, such as nicotine concentration, heavy metals, carbonyl, Aldehydes and Ketones, for the products allowed to be placed on the EU market.
As the second largest market for vaping products after North America, Europe has over 16.74 million adult vapors in 2022, with a market size of USD 5.58 billion (ECigIntelligence). Furthermore, the regional vaping market size is projected to witness a CAGR of 13.17% in the next 6 years.
With only one e-cigarette (Vuse Solo) approved by the U.S. FDA through the Premarket Tobacco Product Application (PMTA) pathway so far, more and more vape brands are aiming for European market, considering its relatively friendly regulatory environment and significant market potential.
As the industry's harm reduction and quality benchmark, SMOORE complies with its in-house SMOORE 3.0 safety standards. Based on the risk assessment guidance of U.S. EPA (Environmental Protection Agency) and PMTA, SMOORE 3.0 covers all of the PMTA vapor safety tests and HPHCs (Harmful and Potentially Harmful Constituents) listed by U.S. FDA. In addition to vapor safety, SMOORE 3.0 also involves extractable and leachable substances of medical-grade atomization materials.
SMOORE fundamental research center has developed a comprehensive analytical testing and risk assessment system, covering PMTA non-clinical testing and health risk assessment. Accredited by China National Accreditation Service for Conformity Assessment (CNAS) in 2019, now it is capable of up to 149 CNAS tests, involving the chemical analysis of e-liquids and aerosols, electrical safety, material safety and battery safety.
Since FEELM, the flagship atomization tech brand belonging to SMOORE, entered the EU market in 2018, SMOORE has been in partnership with several leading vape brands in this region, including Vuse, HEXA, Innocigs and Alfapod. To date, vaping products loaded with FEELM technologies have been exported to Belgium, Netherlands, Estonia, and Romania, with market leadership in the UK, Germany and France.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/48728
View source version on businesswire.com: https://www.businesswire.com/news/home/20220313005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks13.5.2026 13:05:00 CEST | Press release
InStat™ delivers submission-ready tables, lists and figures (TLF) on validated statistical engines, with Clene Nanomedicine as its first customer Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (
Carta Launches Carta Law with Acquisition of Avantia13.5.2026 13:01:00 CEST | Press release
Acquisition marks launch of the largest AI-native law firm for private capital, combining institutional expertise with agent-orchestrated workflows to accelerate fund operations Carta, the agentic enterprise resource planning (ERP) platform for private capital, today announced it has acquired Avantia, a leading AI-powered legal and compliance law firm for asset managers. The acquisition launches Carta Law—the largest AI-native, integrated legal and compliance solution for private markets—unifying legal and compliance workflows with fund operations on a single platform. Private capital firms have long operated with fragmented infrastructure, with fund administration, compliance, and legal services spread across separate vendors. Deal teams wait days for NDAs. Limited partner onboarding to new funds is delayed by KYC backlogs. General counsels lose visibility into legal spend or institutional precedent. As deal velocity increases and regulatory complexity grows, this fragmentation become
Amazfit Unveils the Cheetah 2 Ultra: The Performance Trail Running Watch Built to Master the Toughest Mountain Trails13.5.2026 13:00:00 CEST | Press release
Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Ultra. Building on the momentum of the recently launched Cheetah 2 Pro—designed for road marathoners—the Ultra is a specialized instrument for trail runners who measure success in elevation, unpredictable terrain, and hours spent on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513230718/en/ Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load. Amazfit’s Cheetah 2 Ultra is built for runners who prepare for ultra distances and mountain races, boasting 33-hour trail running optimized GPS b
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights13.5.2026 12:30:00 CEST | Press release
FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 dataCNPV awarded for COMP360 in TRD, further accelerating momentum26-week (Part B) data from COMP006, expected in early Q3 2026Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of yearSuccessful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights. “With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 repr
Uptime Announces Annual Outage Analysis Report 202613.5.2026 12:02:00 CEST | Press release
8th Annual Report analyzes data on IT and data center outages including causes, frequency, costs, and consequences Uptime Institute today announced the release of its 8th Annual Outage trends report, an ongoing series from Uptime Institute Intelligence analyzing IT service resiliency. Outage prevention continues to be a central focus for data center operators as demand growth, AI-driven workloads and power constraints reshape risk profiles. As design and operations improve, operators must still navigate greater system complexity, grid instability, deeper interdependencies and evolving external threats. The 8th Annual Outage Analysis 2026 report analyzes recent data on the causes, frequency and consequences of IT and data center outages. For the fifth consecutive year, Uptime Intelligence Research suggests that outage frequency on a per-site basis is declining. However, the pace of improvement has slowed compared to previous years and approximately 1 in 10 note their last outage had ser
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
